uniQure N.V. (NASDAQ:QURE) Stock Has Average Target Price of $59.55

by · The Markets Daily

uniQure N.V. (NASDAQ:QURE – Get Free Report) has received a consensus rating of “Moderate Buy” from the sixteen analysts that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have assigned a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $59.55.

Several research analysts have recently commented on the company. Royal Bank Of Canada boosted their target price on uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a report on Thursday, June 18th. Barclays cut their price objective on uniQure from $65.00 to $60.00 and set an “overweight” rating for the company in a research report on Thursday, July 30th. Cantor Fitzgerald raised uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price objective on the stock in a research note on Wednesday, June 17th. Mizuho increased their target price on uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a report on Thursday, June 25th. Finally, Wall Street Zen lowered uniQure from a “hold” rating to a “sell” rating in a research note on Saturday, September 5th.

Get Our Latest Stock Report on QURE

uniQure Trading Up 2.3%

Shares of uniQure stock opened at $39.11 on Friday. The stock has a market capitalization of $2.71 billion, a P/E ratio of -9.75 and a beta of 0.94. The company has a quick ratio of 10.01, a current ratio of 10.01 and a debt-to-equity ratio of 0.15. The company has a 50-day simple moving average of $44.57 and a 200 day simple moving average of $33.25. uniQure has a 12-month low of $8.73 and a 12-month high of $71.50.

uniQure (NASDAQ:QURE – Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40). The firm had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.45 million. uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. During the same quarter last year, the firm earned ($0.69) earnings per share. Research analysts expect that uniQure will post -3.82 earnings per share for the current fiscal year.

Insider Buying and Selling

In other uniQure news, CEO Matthew Kapusta sold 21,082 shares of the stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $45.16, for a total transaction of $952,063.12. Following the sale, the chief executive officer owned 519,227 shares of the company’s stock, valued at $23,448,291.32. This represents a 3.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.65% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On uniQure

A number of large investors have recently modified their holdings of QURE. Avoro Capital Advisors LLC lifted its holdings in uniQure by 38.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after buying an additional 1,705,556 shares in the last quarter. Orbimed Advisors LLC increased its stake in shares of uniQure by 189.7% in the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock valued at $34,926,000 after buying an additional 1,398,749 shares during the period. Artia Global Partners LP increased its stake in shares of uniQure by 55.4% in the 4th quarter. Artia Global Partners LP now owns 1,023,539 shares of the biotechnology company’s stock valued at $24,493,000 after buying an additional 364,700 shares during the period. Assenagon Asset Management S.A. raised its position in shares of uniQure by 249.9% during the second quarter. Assenagon Asset Management S.A. now owns 513,530 shares of the biotechnology company’s stock worth $23,653,000 after acquiring an additional 366,781 shares during the last quarter. Finally, Fiera Capital Corp bought a new stake in shares of uniQure during the fourth quarter worth $18,390,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About uniQure

(Get Free Report)

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) technology to deliver genetic material intended to address the underlying causes of disease, with research activities spanning neurological, neuromuscular, metabolic and cardiovascular conditions.

uniQure’s pipeline has included AMT-130, an investigational gene therapy for Huntington’s disease, as well as programs targeting other conditions such as amyotrophic lateral sclerosis and Fabry disease.

Recommended Stories